Preclinical evaluation of antitumor activity of the proteasome inhibitor MLN2238 (ixazomib) in hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is one of the common malignancies and is an increasingly important cause of cancer death worldwide. Surgery, chemotherapy, and radiation therapy extend the 5-year survival limit in HCC patients by only 6%. Therefore, there is a need to develop new therapeutic approache...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Death Dis
Main Authors: Augello, Giuseppa, Modica, Martina, Azzolina, Antonina, Puleio, Roberto, Cassata, Giovanni, Emma, Maria Rita, Di Sano, Caterina, Cusimano, Antonella, Montalto, Giuseppe, Cervello, Melchiorre
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group UK 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833482/
https://ncbi.nlm.nih.gov/pubmed/29348495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41419-017-0195-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados